Dyadic Welcomes New Chief Operating Officer
News May 10, 2013
Dyadic International, Inc. has announced that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June.
Brooks joins Dyadic from J.P. Morgan where he served as a Vice President in the firm’s Investment Bank.
“Danai has significant financial and operational experience in the renewable energy and bio-based chemical space, and will be a tremendous asset to Dyadic,” said Mark Emalfarb, Dyadic’s President and Chief Executive Officer.
Emalfarb continued, “As EVP and COO, Danai will play a key role in driving our business development and licensing efforts, as well as corporate strategic planning and operational improvements across the globe.”
“As a long-time advisor to Dyadic, I am intimately familiar with the Company and thrilled to have the opportunity to join the team” said Brooks.
Brooks continued, “Dyadic continues to compete with larger industrial enzyme companies using its game-changing C1 enzyme expression platform. Together, we will continue to build commercial momentum through enzyme sales and strategic partnerships across a wide range of sectors including cellulosic biofuels, biopharmaceuticals and industrial applications. We look forward to introducing new C1-based products to the many industries and companies that can benefit from C1’s ability to produce enzymes and other proteins with class leading performance.”
While at J.P. Morgan, Brooks advised clients across a broad spectrum of sectors, including chemicals, renewable energy and industrials.
He has held senior operational, engineering and manufacturing positions with Dell Inc., Mars Inc. and Ford Motor Company.
He received a B.S. in Industrial Engineering and Master of Engineering from Cornell University, a Master of Engineering Management from Northwestern University and an MBA from Northwestern’s Kellogg School of Management.
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Antibody Shrinks Tumors of Patients with Advanced Skin CancerNews
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer.READ MORE